Home ›
Leukemia Trials ›
NCT05289687
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
Trial Details
NCT ID NCT05289687
Phase PHASE2
Sponsor Eastern Cooperative Oncology Group
Status RECRUITING
Cancer Type Leukemia
Interventions Daratumumab / Hyaluronidase Injection
Locations (sample) Chicago, Illinois, United States|41.85003,-87.65005
Key Eligibility Criteria
Patient must have documented T cell ALL and must be in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy. Patients in hematologic CR or CRi must have persistent or recurrent MRD ≥ 10-4. Institution must have received central MRD status test results confirming persistent or recurrent MRD ≥ 10-4 by flow cytometry. Patient may have undergone a prior allogeneic stem cell transplant, but patient may not have Grafts Versus Host Disease (GVHD) that requires ongoin…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →